Advancing Artificial Insemination: The AI-Port Spring Trial Shows Promise
Innovations in artificial insemination (AI) are revolutionising the breeding industry, and Memphasys is at the…
The gathering storm: One in twenty men are infertile
"The human male was not a very fertile individual. Roughly one in 20 is infertile ... An old lecturer of mine used to…
Memphasys progresses freeze-free semen transporter
Reproductive technology company Memphasys has announced findings from a trial at a stud farm of its semen storage and…
Watch: The future of infertility treatment
Dr Ramya Jayaram addressed ASPIRE 2023, the 12th Congress of the Asia Pacific Initiative on Reproduction, to present…
Memphasys Expands Global Reach: Exclusive Distribution Agreements Signed for Canada and New Zealand
In a significant stride towards global expansion, we have announced an exclusive distribution agreement with Vitrolife…
FelixTM: Viewpoint from Japan
As the first major global commercial agreement to sell and distribute the FelixTM sperm separation device goes from…
Memphasys accelerates commercial approval for sperm-separation device
Memphasys recently signed an exclusive distribution agreement with Vitrolife Japan KK, a subsidiary of the Vitrolife…
Why FelixTM is big in Japan
Memphasys recently signed an exclusive distribution agreement with Vitrolife Japan KK, a subsidiary of the Vitrolife…
Fantastic Austrade support for Felix in Japan
Memphasys recently signed an exclusive distribution agreement with Vitrolife Japan KK, a subsidiary of the Vitrolife…
Watch: Understanding male fertility
Laureate Professor John Aitken, Scientific Director at Memphasys, and Professor Robert McLachlan, Endocrinologist and…